The sequencing data of Kasum-9 and M2B9Q cells harboring the MEF2D fusion gene following CUDC-907 treatment

The MEF2D fusion gene defines a high-risk BCP-ALL subgroup with distinct phenotypic characteristics. Through high-throughput drug screening, we identified that CUDC-907 exhibits potent therapeutic efficacy against this BCP-ALL subtype. We treated Kasum-9 and M2B9Q cells harboring the MEF2D fusion gene with DMSO and CUDC-907 respectively, followed by performing RNA-seq and ChIP-seq analyses.